Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Potential lack of drug interactions for the SERMs droloxifene and lasofoxifene

Nov. 30, 1999

GW-395058 assessed for pharmacokinetics and effects on platelets in monkeys

Nov. 30, 1999

(Anti)-estrogenic compounds designed at HMR for osteoporosis

Nov. 30, 1999

Phase I clinical trial of Ushercell completed

Nov. 30, 1999

Gender does not affect PK of Sch-58235: results presented at 1999 AAPS

Nov. 26, 1999

Calcimimetics and calcilytics designed at NPS

Nov. 26, 1999

Once-weekly Fosamax as effective as daily dosing

Nov. 26, 1999

AxyS and Merck extend osteoporosis collaboration

Nov. 26, 1999

Sawai discovers selective beta3-adrenoceptor agonist with potential as diabetes Rx

Nov. 25, 1999

Weizmann reports success in developing vanadium-based antidiabetic drugs

Nov. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...